Helus Pharma Inc. Common Stock HELP
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $45.00 (+281.4% upside)
Key Stats
- Today's Range
- $10.45 – $12.09
- 50-Day Range
- $7.51 – $15.15
- 52-Week Range
- $3.76 – $15.15
- Volume
- 1.66 million shs
- Average Volume
- 1.61 million shs
- Market Cap
- $862.22 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 3.85%
- Days to Cover
- 5.27
About Helus Pharma Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Related Stocks
Compare head-to-head: HELP vs NVDA·HELP vs AAPL·HELP vs GOOGL·HELP vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.